论文部分内容阅读
目的观察左卡尼汀联合重组人促红细胞生成素治疗肾性贫血的临床治疗效果。方法 48例尿毒症应用血液透析的患者作为研究对象,将其随机分为两组,各24例。对照组在血液透析后在皮下注射重组人促红细胞生成素,观察组在对照组治疗的基础上增加左卡尼汀静脉注射,两组患者治疗周期为12周。对比两组患者的临床治疗效果。结果观察组血红蛋白(Hb)和血细胞比容(Hct)明显高于对照组(P<0.05);治疗12周后,观察组促红细胞生成素的用量明显变长(P<0.05);对照组患者重组人促红细胞生成素的用量与治疗前对比差异无统计学意义(P>0.05)。结论应用左卡尼汀可以有效降低重组人促红细胞生成素用量,还能提高重组人促红细胞生成素的临床治疗效果,使肾性贫血得到改善,建议临床推广应用。
Objective To observe the clinical effect of levocarnitine combined with recombinant human erythropoietin in the treatment of renal anemia. Methods 48 patients with uremia hemodialysis patients as the research object, they were randomly divided into two groups, each 24 cases. The control group was subcutaneously injected with recombinant human erythropoietin after hemodialysis. The observation group received intravenous injection of levocarnitine on the basis of the control group, and the treatment period was 12 weeks in both groups. The clinical effects of two groups were compared. Results The hemoglobin (Hb) and hematocrit (Hct) in the observation group were significantly higher than those in the control group (P <0.05). After 12 weeks of treatment, the dosage of erythropoietin in the observation group was significantly longer (P <0.05) There was no significant difference in the dosage of recombinant human erythropoietin compared with that before treatment (P> 0.05). Conclusion The application of levocarnitine can effectively reduce the dosage of recombinant human erythropoietin, but also improve the clinical therapeutic effect of recombinant human erythropoietin so that renal anemia can be improved, so it is recommended for clinical application.